Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery
Exalpha Biologicals, Inc.

Progesterone receptor

  • Product Code: X1437M
  • Size: 100 µg
  • Price (USD): $528

Cat #

X1437M		 Quantity:      

Data Sheet

Product Name

Progesterone receptor

Host/Source

Mouse

Clone

hPRa2 + hPRa3

Isotype

IgG

Product Type

Monoclonal Antibody

Reactivity

Human, Horse, Pig

Applications

Western Blot, Immunoprecipitation, Immunohistochemistry (Paraffin & Frozen sections), Immunofluorescense

Purification

Protein A/G Chromatography

Size

100 µg

Price (USD)

$528

Background

Equally recognizes two proteins: 116kDa (triplet) and 81kDa (singlet), identified as the hormone-binding high (B) and low (A) MW forms of human PgR. Expression of PgR has been suggested to reflect a intact estrogen regulatory machinery and therefore, predict better clinical response to endocrine therapy than ER alone. This antibody is excellent for immunohistochemical staining of formalin/paraffin tissues.

Immunogen

Hybridoma produced by the fusion of splenocytes from RBF/DN mice immunized with PgR from a human endometrial carcinoma (EnCa 101) grown in athymic mice and mouse myeloma HL-1 Friendly cells.

Positive Control

T47D or breast carcinoma

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Product Image

Image Legend

Immunohistochemical staining using progesterone receptor antibody on formalin fixed, paraffin embedded human breast carcinoma.

Database Links:

SwissProtO00264Human

References

1. Satyaswaroop PG. Development of a preclinical model for hormonal therapy of human endometrial carcinomas. Annals of Medicine, 1993, 25:105-11. 2. Shyamala G; et al. Relationship between 90-kilodalton heat shock protein, estrogen receptor, and progesterone receptor in human mammary tumors. Breast Cancer Research and Treatment, 1993, 26(1):95-100. 3. Satyaswaroop PG; et al. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Letters, 1992, 62(2):107-14. 4. Clarke CL; et al. Direct transcriptional regulation of the progesterone receptor by retinoic acid diminishes progestin responsiveness in the breast cancer cell line T-47D. Journal of Biological Chemistry, 1991 Oct 5, 266(28):18969-75. 5. Schneider W; et al. Murine progesterone receptor exists predominantly as the 83-kilodalton 'A' form. Journal of Steroid Biochemistry and Molecular Biology, 1991, 38(3):285-91. 6. Mortel R; et al. Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. American Journal of Obstetrics and Gynecology, 1990, 162(4):928-34; discussion 934-6. 7. Clarke CL; et al. Progesterone receptor regulation by retinoic acid in the human breast cancer cell line T-47D. Journal of Biological Chemistry, 1990 Jul 25, 265(21):12694-700. 8. Clarke CL. Cell-specific regulation of progesterone receptor in the female reproductive system. Molecular and Cellular Endocrinology, 1990 May 7, 70(3):C29- 33. 9. Satyaswaroop PG; Mortel R. Hormonal treatment of endometrial carcinoma: an overview and new development in biology. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37(6):997-1001. 10. Shyamala G; Schneider W; Schott D. Developmental regulation of murine mammary progesterone receptor gene expression. Endocrinology, 1990 Jun, 126(6):2882-9. 11. Alexander IE; Clarke CL; Shine J; Sutherland RL. Progestin inhibition of progesterone receptor gene expression in human breast cancer cells. Molecular Endocrinology, 1989 Sep, 3(9):1377-86. 12. Feil PD; Clarke CL; Satyaswaroop PG. A polyclonal antiserum against the rabbit progesterone receptor recognizes the human receptor: biochemical characterization. Cell Biochemistry and Function, 1989, 7(2):139-46. 13. Satyaswaroop PG; Zaino RJ; Mortel R. Carcinoma of the endometrium and hormonal receptors. Cancer Treatment and Research, 1989, 49:71-92. 14. Tabibzadeh SS; Satyaswaroop PG. Sex steroid receptors in lymphoid cells of human endometrium. American Journal of Clinical Pathology, 1989, 91(6):656-63. 15. Zaino RJ; Clarke CL; Feil PD; Satyaswaroop PG. Differential distribution of estrogen and progesterone receptors in rabbit uterus detected by dual immunofluorescence. Endocrinology, 1989, 125(5):2728-34. 16. Feil PD; Clarke CL; Satyaswaroop PG. Progesterone receptor structure and protease activity in primary human endometrial carcinoma. Cancer Research, 1988, 48(5):1143-7. 17. Feil PD; Clarke CL; Satyaswaroop PG. Progestin- mediated changes in progesterone receptor forms in the normal human endometrium. Endocrinology, 1988, 123(5):2506-13. 18. Zaino RJ; Clarke CL; Mortel R; Satyaswaroop PG. Heterogeneity of progesterone receptor distribution in human endometrial adenocarcinoma. Cancer Research, 1988, 48(7):1889-95. 19. Clarke CL; Feil PD; Satyaswaroop PG. Progesterone receptor regulation by 17 beta-estradiol in human endometrial carcinoma grown in nude mice. Endocrinology, 1987, 121(5):1642-8. 20. Satyaswaroop PG; Zaino R; Clarke CL; Mortel R. Nude mouse system in the study of tumor biology, treatment strategies and progesterone receptor physiology in human endometrial carcinoma. Journal of Steroid Biochemistry, 1987, 27(1-3):431-8. 21. Satyaswaroop PG; Zaino RJ; Mortel R. Steroid receptors and human endometrial carcinoma: studies in a nude mouse model. Cancer Metastasis Reviews, 1987, 6(3):223-41. 22. Clarke CL; et. al. Endocrinology, 1987, 121:1123-32. 23. Gray GO; Satyaswaroop PG. Biochem Biophys Res Comm, 1988, 157(3):1067-77.